Zoetis stock has had a tough run over the last few years, yet the current valuation checks suggest the shares may now be pricing in a lot of that bad news. After a prolonged slide, the question is whether the current market price properly reflects Zoetis' earnings power and risks. Over the past 5 years, Zoetis shareholders have seen the share price decline about 61.8%, which points to a significant reset in expectations. Recent investor focus is on how competition and softer pet care...

Zoetis recently received an Emergency Use Authorization from the U.S. FDA for its Simparica Trio chewable to treat life-threatening New World screwworm infestations in dogs and puppies, while also appointing experienced healthcare executive Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer. At the same time, Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...

Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.

These stocks have been generous with their dividend increases, and more may be on the way.

William Grogan will take over the chief finance job vacated by Jay Saccaro. Stifel analysts called Grogan’s “no-nonsense” mindset on setting expectations a strength.

Zoetis (NYSE:ZTS) is an animal health company. Michael Burry is long the stock, several media outlets reported, citing his Substack disclosures. The stock is down about 40% so far this year. Let’s break down whether it’s worth buying. Why Burry Likes It Burry’s pitch is simple. Zoetis has dropped more than 70% from its 2021 […]

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Zoetis delivered flat revenue in Q2, missing Wall Street expectations, while its adjusted earnings per share slightly exceeded consensus. The market’s positive reaction was underpinned by management’s acknowledgment of intensifying competitive pressures in key Companion Animal categories and ongoing declines in U.S. veterinary clinic visits. CEO Kristin Peck noted, “Veterinary clinic visits declined across markets, extending a multiyear trend that has occurred alongside price increases that have

Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q2 2026 investor letter. A copy of the letter can be downloaded here. Polen Focus Growth returned 6.33% (net of fees) in the second quarter of 2026, significantly underperforming the Russell 1000 Growth Index’s 16.74% gain, as the market rally remained narrowly focused on AI […]

The FDA authorized Zoetis’s Simparica TRIO—already sold since 2020 for heartworm, fleas and ticks—for treating New World screwworm in dogs and puppies.

U.S. companion animal demand weakened, but livestock and diagnostics surged.

'The Big Short' investor is betting against AI-linked names even as he sees strong demand for compute as a potential warning sign for the sector.

Famed "Big Short" investor Michael Burry buys new out-of-the-money puts on Palantir and adds to his Zoetis stake.

Zoetis has considerably underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Brown Advisory, an investment management company, released its “Brown Advisory Global Leaders Strategy” for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory’s Global Leaders Strategy delivered a net return of 4.6% in the second quarter of 2026, underperforming its benchmark, the MSCI ACWI Net Index, […]